Previous 10 | Next 10 |
AIMIA REPORTS FOURTH QUARTER 2022 RESULTS Canada NewsWire (All figures in Canadian dollars unless otherwise noted) TORONTO , March 16, 2023 /CNW/ - Aimia Inc. (TSX: AIM) reported its financial results for the three months and twelve months ended De...
AIMIA DECLARES PREFERRED SHARE DIVIDENDS Canada NewsWire TORONTO , March 16, 2023 /CNW/ - Aimia (TSX: AIM) announced today that the Board of Directors has declared quarterly dividends on each series of its preferred shares: a quarterly dividend in the amoun...
2023-03-14 09:00:01 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for tho...
2023-03-08 10:20:38 ET AIM ImmunoTech <<AIM>> announces the publication of a new analysis of the ability of its drug Ampligen (rintatolimod) to inhibit the spread and replication of Ebola virus disease (EVD), which adds to the body of evidence supporting Ampligenȁ...
OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral disea...
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and scientific communities Poised to achieve multiple clinical and regulatory value-driving...
OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseas...
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseas...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday! Moving stocks this morning are earnings reports, clinical tria...
A Florida-based %Biotech company captured the attention of the trading community on Tuesday after it was announced that it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca, according to today’s press release. This news...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...